These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12696464)

  • 1. [Lessons from the Women's Health Initiative (WHI) using hormone replacement therapy with regard to heart disease--the dream that has been broken?].
    Pines A
    Harefuah; 2003 Mar; 142(3):163-5, 240. PubMed ID: 12696464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.
    Hillman JJ; Zuckerman IH; Lee E
    J Womens Health (Larchmt); 2004 Nov; 13(9):986-92. PubMed ID: 15665655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002).
    Barber CA; Margolis K; Luepker RV; Arnett DK
    J Womens Health (Larchmt); 2004 Nov; 13(9):975-85. PubMed ID: 15665654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician].
    Gaspard U; van den Brûle F; Pintiaux A; Foidart JM
    Rev Med Liege; 2002 Aug; 57(8):556-62. PubMed ID: 12405030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
    Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitfalls of the WHIs: Women's Health Initiative.
    Mastorakos G; Sakkas EG; Xydakis AM; Creatsas G
    Ann N Y Acad Sci; 2006 Dec; 1092():331-40. PubMed ID: 17308158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the WHI: HRT requires a cautious and individualized approach.
    Aubuchon M; Santoro N
    Geriatrics; 2004 Nov; 59(11):22-6. PubMed ID: 15615157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of hormone therapy in the 50-59 year age group.
    van de Weijer PH
    Maturitas; 2008 May; 60(1):59-64. PubMed ID: 18556157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What is the actual lesson from the WHI study upon its completion?].
    Pines A
    Harefuah; 2004 Oct; 143(10):722-3, 766. PubMed ID: 15521348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.